Auxilium Pharmaceuticals — Investor Presentation (September 2010)
50 slides from Auxilium Pharmaceuticals's investor presentation, Sep 13, 2010
Slide 1: September 2010
September 2010 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the pricing, time to market, size of market,
Slide 3: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates
Slide 4: Slide 4
Slide 5: XIAFLEX – Unique Blockbuster Opportunity
XIAFLEX – Unique Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s Contracture in U.S. Phase III trial in Peyronie’s disease expected to start by end of 2010 • Well-characterized mode of action •
Slide 6: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th
Slide 7: Treatment Options Historically Limited to Invasive Surgery
Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids
Slide 8: It Is About the Patient
It Is About the Patient Pre-XIAFLEX treatment 30 days post-single injection of XIAFLEX Immediately post-operative Intra-operative open fasciectomy Pictures courtesy of Dr. Clayton Peimer
Slide 9: XIAFLEX Offers a Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers a Nonsurgical Treatment for Dupuytren’s Contracture
Slide 10: A Significant Number of Dupuytren's Contracture Patients Benefited from XIAFLEX
A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX
Slide 11: Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach N=125
Slide 12: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of
Slide 13: Contracture Recurrence Affects Patients
Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following surger
Slide 14: Two Year Recurrence Rate of 19.3% for XIAFLEX in Dupuytren's Contracture
Two Year Recurrence Rate of 19.3% for XIAFLEX in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with Re
Slide 15: Launch Update Through August 2010
Launch Update Through August 2010
Slide 16: Key Objectives for U.S. XIAFLEX Launch in 2010
Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest
Slide 17: Targeting the Eligible Patient Population Should Drive Development of the U.S. Market
Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% database also use
Slide 18: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini
Slide 19: Unique Sales Cycle for Targeted Physicians
Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE
Slide 20: Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate
Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling 11 – 21 week
Slide 21: Reimbursement Processes Are New to Target Physicians
Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use effective as of July 1, 2010 • CMS has recommended a J-Code for
Slide 22: Over 1,800 physicians and 1,300 sites have enrolled
Over 1,800 physicians and 1,300 sites have enrolled 1,853 1,307 Feb Mar Apr May Jun Jul Aug PHYSICIANS SITES
Slide 23: Leading Indicators Trending Positively - Cumulative Call Center Volume
Leading Indicators Trending Positively - Cumulative Call Center Volume
Slide 24: Leading Indicators Trending Positively - Cumulative unique sites that have ordered XIAFLEX
Leading Indicators Trending Positively - Cumulative unique sites that have ordered XIAFLEX Mar Apr May Jun Jul Aug number of sites
Slide 25: Some Sites Moving from Test Drive to Increasing Usage
Some Sites Moving from Test Drive to Increasing Usage Injections per Site
Slide 26: ~91% of insured lives have access
~91% of insured lives have access
Slide 27: Out of Pocket Costs In Line With Expectations
Out of Pocket Costs In Line With Expectations % Of Treatment Cost Paid by Patient 55% 5% 7% 8% 23% 2% 0% 10% 20% 30% 40% 50% 60% 0% Up to 2% 2.1-9.9% 10-19.9% 20% >20% A significant portion of Medicare patients with a 20% liability have secondary insurance, which may cover a portion of this cost
Slide 28: Distribution Network is Operating Smoothly
Distribution Network is Operating Smoothly
Slide 29: Direct to Patient Program Launching
Direct to Patient Program Launching
Slide 30: Other Patient Programs Launching
Other Patient Programs Launching • XIAFLEX facebook.com webpage • XIAFLEX.com re-design • XIAFLEX and Dupuytren’s contracture WebMD pages • Handraisers.com
Slide 31: We Believe Launch Strategy Is Sound
We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good • Usage is characterized by “test driving”, which is typical for paradigm changing treatment • Payers willing to provide access to drug and procedures • All di
Slide 32: Sustainable Blockbuster Market for Dupuytren's Contracture Anticipated
Sustainable Blockbuster Market for Dupuytren’s Contracture Anticipated • High disease prevalence Based on literature, ~ 6M to 11M patients in U.S. have a Dupuytren’s pit, nodule or cord, but only ~ 300,000 new patients annually diagnosed in U.S. • Sustainable patient pool New patients within an agei
Slide 33: XIAFLEX I.P. Position for Dupuytren's Contracture
XIAFLEX I.P. Position for Dupuytren’s Contracture • U.S. Orphan Drug designation granted on May 23, 1996 provides exclusivity for 7 years post-approval in February 2010 • Market Exclusivity expected in U.S. for 12 years post-approval, per 2010 Patient Protection and Affordable Care Act • Market Excl
Slide 34: Peyronie's Disease is a Devastating Disorder
Peyronie’s Disease is a Devastating Disorder Smith BH. Am J Clin Pathol . 1966;45:670 - 678. Somers KD, Dawson DM. J Urol . 1997;157:311-315. • Scarring phenomenon affecting the tunica albuginea • Plaques show excessive collagen deposition • Potential Symptoms > Pain with erection, penile curvature/
Slide 35: Peyronie's Disease - an Unmet Medical Need
Peyronie’s Disease - an Unmet Medical Need Schwarzer U, The prevalence of Peyronie’s disease: Results of a large survey. BJU Int 2001;88:727-30; Mulhall et al: J Urology 2004:171: 2350 - 2353;Rhoden et al: Int J. Impot Res 2001 :13 : 291 - 293; La Pera et al : EUR Urology 2001: 40 :525 - 530. Smith
Slide 36: Current Surgical Options Are the Treatment of Last Resort
Current Surgical Options Are the Treatment of Last Resort • The goal of surgery is simply to make the two sides of the penis equal in size through reduction of the longer side • Post-surgically, graft or prosthetic may be required • Cost of surgery in U.S. is ~$10-12K • Patients are highly motivated
Slide 37: Unapproved Treatments for Peyronie's Disease Have Been Used With Little Reported Success
Unapproved Treatments for Peyronie’s Disease Have Been Used With Little Reported Success • Verapamil • Vitamin E • Colchicine • Potassium aminobenzoate (Potaba) • Tamoxifen • Interferon alpha-2a • Corticosteroids • Energy transfer treatment including extracorporeal shock wave therapy (ESWT), laser a
Slide 38: Promising Phase IIb Data in Peyronie's Disease
Promising Phase IIb Data in Peyronie’s Disease • Overall – Significant XIAFLEX effect – Reduction of penile curvature – Improvement in Peyronie’s Disease Bother (PRO Domain) • XIAFLEX With Modeling – Significant effect in both penile curvature and Peyronie’s disease bother endpoints • XIAFLEX Withou
Slide 39: Strategic Partnership with Pfizer for XIAFLEX in EU
Strategic Partnership with Pfizer for XIAFLEX in EU • Strong working relationship with goal to obtain EMA approval • Auxilium is primarily responsible for the global development of XIAFLEX, including all clinical & commercial manufacturing and supply. • Pfizer is primarily responsible for: European
Slide 40: Auxilium
| Auxitium rer innovations for tite
Slide 41: Testim Maintains Double-Digit Growth in Testosterone Replacement Therapy Market
Testim ® Maintains Double-Digit Growth in Testosterone Replacement Therapy Market *Mulligan T. et al. Int J. Clin Pract • Proprietary, topical 1% testosterone gel > Once-a-day application > Favorable clinical and commercial profile • Recent study indicates 39% of U.S. males over 45 yrs are hypogonad
Slide 42: Patient Results Were Proven in Clinical Studies
Patient Results Were Proven in Clinical Studies • 16 clinical studies involving approx. 1,800 patients > largest placebo-controlled study ever conducted • Clinical trial of Testim vs. AndroGel ® > Testim provides 30% higher testosterone absorption (p<0.001)
Slide 43: Gels Continue to Drive Significant Growth in TRT Marketplace
Gels Continue to Drive Significant Growth in TRT Marketplace Source: IMS data
Slide 44: Continuing Track Record of Consistent Revenue Growth
Continuing Track Record of Consistent Revenue Growth
Slide 45: Testim Patent Coverage
Testim Patent Coverage *Note: The referenced Testim patents are owned by CPEX Pharmaceuticals, Inc. U.S. • U.S. Patent # 7,320,968* covering method of use claims for Testim issued January 22, 2008; expires 2025 • 6 additional U.S. Patents (# 7,608,605 through 610*) covering method of use claims for
Slide 46: FDA Has Granted Our Citizen's Petition In Part And Denied It In Part
FDA Has Granted Our Citizen's Petition In Part And Denied It In Part • Auxilium’s Citizen’s Petition was filed in February 2009 and FDA response was received in August 2009. • FDA has agreed with some of the statements we made in our Citizen's Petition regarding the testing required for generic vers
Slide 47: 2010 Financial Results and 2010 Guidance
Testim Revenues $91.6 $72.1 $185-195 XIAFLEX Revenues $4.3 $1.8 N/A R&D Expense* $19.6 $27.3 $50-60 SG&A Expense* $77.3 $55.8 $160-170 Net Loss ($22.1) ($26.0) N/A Stock – Based Comp Expense (* included) $8.4 $9.4 $22-25 Cash & Cash Equivalents $165.0 2010 Financial Results and 2010 Guidance ($ Mill
Slide 48: Auxilium's Plan to Provide Visibility on XIAFLEX Launch
Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • For 3Q 2010, we anticipate that XIAFLEX net revenues will be in the range of $5.5 million to $6.5 million, including approximately $1.1 million in revenue recognized from milestones previously received under the Pfizer contract. • We will con
Slide 49: Strategic Priorities in 2010
Strategic Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EU Dupuytren’s submission and prepare for their eventual launch; • Commence phase III for XIAFLEX in Peyronie’s disease by year end of 2010;
Slide 50: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value Note: Seeking partners for Transmucosal film product candidates
Auxilium Pharmaceuticals — Investor Presentation (September 2010) on 6ix